[ABSTRACT]

The present invention relates to a modified IgG4 Fc fragment useful as a drug carrier. When the modified IgG4 Fc fragment of the present invention is combined with an arbitrary drug, the resulting drug conjugate can minimize the effector functions of the IgG4 Fc and the chain exchange with *in vivo* IgG while maintaining *in vivo* activity and improving *in vivo* duration of the drug conjugate.